Respiratorius AB

XSAT:RESP (Sweden)  
kr 0.10 (-14.19%) May 23
At Loss
P/B:
1.07
Market Cap:
kr 28.47M ($ 2.65M)
Enterprise V:
kr 26.52M ($ 2.47M)
Volume:
3.38M
Avg Vol (2M):
613.78K
Also Trade In:
Volume:
3.38M
At Loss
Avg Vol (2M):
613.78K

Business Description

Description
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.95
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 3.96
9-Day RSI 11.24
14-Day RSI 20.17
6-1 Month Momentum % 2.97
12-1 Month Momentum % -3.48

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.73
Quick Ratio 1.73
Cash Ratio 1.54

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.6
Name Current Vs Industry Vs History
ROE % -20.61
ROA % -19.91
ROIC % -20.15
ROC (Joel Greenblatt) % -115.78
ROCE % -20.61

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 1.07
EV-to-EBIT -4.37
EV-to-EBITDA -7.75
EV-to-FCF -11.44
Earnings Yield (Greenblatt) % -22.85
FCF Yield % -19.7